title: Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
abstract: BACKGROUND
  The field of acute coronary syndromes is characterised by an increasing tendency towards early invasive catheter-based diagnostics and therapeutics-a practice based on observational and retrospective data.
  
  
  OBJECTIVE
  To compare immediate versus deferred angioplasty in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) METHODS: A randomised, prospective multicentre trial was performed in patients admitted with NSTE-ACS, eligible for percutaneous coronary intervention (PCI). Interim analysis was performed after enrolment of 251 patients; PCI was appropriate in 142 patients. These patients were randomised to immediate PCI (n = 73) or deferred PCI (24-48 h) (n = 69). Patients received protocol-driven glycoprotein IIb/IIIa blockers, aspirin and clopidogrel. The primary end point was a composite of death, non-fatal myocardial infarction (MI) or unplanned revascularisation, at 30 days. After hospital discharge outpatient follow-up was performed at 30 days and 6 months.
  
  
  RESULTS
  The incidence at 30 days of the primary end point was 60% in the group receiving immediate PCI and 39% in the group receiving deferred PCI (relative risk (RR) = 1.5, 95% CI 1.09 to 2.15; p = 0.004). No deaths occurred in either group. MI was significantly more common in the group receiving immediate PCI (60% vs 38%, RR = 1.6, 95% CI 1.12 to 2.28, p = 0.005). Unplanned revascularisation was similar in both groups. The observed difference was preserved over 6-months' follow-up.
  
  
  CONCLUSIONS
  Immediate PCI was associated with an increased rate of MI in comparison with a 24-48 h deferred strategy, despite aggressive antithrombotic treatment. The results suggest that PCI for high-risk patients with non-refractory NSTE-ACS should be delayed for at least 24 h after hospital admission.
  
  
  BACKGROUND
  ISRCTN80874637.
authors.affiliation: Onze Lieve Vrouwe Gasthuis, Department of Interventional Cardiology, Amsterdam, The Netherlands. R.K.Riezebos@xs4all.nl
authors.forename: R K
authors.initials: RK
authors.lastname: Riezebos
authors.forename: E
authors.initials: E
authors.lastname: Ronner
authors.forename: E
authors.initials: E
authors.lastname: Ter Bals
authors.forename: T
authors.initials: T
authors.lastname: Slagboom
authors.forename: P C
authors.initials: PC
authors.lastname: Smits
authors.forename: J M
authors.initials: JM
authors.lastname: ten Berg
authors.forename: F
authors.initials: F
authors.lastname: Kiemeneij
authors.forename: G
authors.initials: G
authors.lastname: Amoroso
authors.forename: M S
authors.initials: MS
authors.lastname: Patterson
authors.forename: M J
authors.initials: MJ
authors.lastname: Suttorp
authors.forename: J G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: G J
authors.initials: GJ
authors.lastname: Laarman
mesh_terms: D054058:Acute Coronary Syndrome / Q000401:mortality / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin